Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EFFECT-HF: Ferinject for Exercise Capacity in Heart Failure
NCT01394562Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Jul 2011
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ferric carboxymaltose in iron deficiency anemia (IDA), sponsored by CSL Vifor. Started Jul 2011; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT01394562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394562.